Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California supplement AER bill

This article was originally published in The Tan Sheet

Executive Summary

SB 779, which would require quarterly supplement AE reporting and charge fees to manufacturers for implementation, was held in the Assembly Committee and will not be revisited until 2004 legislative session. Bill faced opposition from CHPA, AHPA, NNFA, several firms due to its lack of specifics regarding AE info required, allocation of fees. Sponsored by Jackie Speier (D), bill passed Senate June 2 (1"The Tan Sheet" June 30, 2003, In Brief)...

You may also be interested in...



Will California Supplement Field Flourish Under Schwarzenegger’s Watch?

California Republican Governor-elect Arnold Schwarzenegger's pro-business stance and fitness industry background may create an environment friendly to the state's large dietary supplement industry

California AER bill

Legislation requiring quarterly adverse event reporting to state's Department of Health Services by distributors, manufacturers of supplements is slated for July 8 hearing in Assembly Health Committee. SB 779 excludes products containing only vitamins, minerals. Under bill, health department would be authorized to collect fees and establish Dietary Supplement Consumer Complaint Fund. CHPA, NNFA, Herbalife oppose bill, which passed Senate June 2...

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

Topics

UsernamePublicRestriction

Register

PS095672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel